AlphaMark Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $10K | Hold |
105
| – | – | ﹤0.01% | 447 |
|
|
2024
Q3 | $9K | Hold |
105
| – | – | ﹤0.01% | 524 |
|
|
2024
Q2 | $7K | Hold |
105
| – | – | ﹤0.01% | 574 |
|
|
2024
Q1 | $8K | Hold |
105
| – | – | ﹤0.01% | 563 |
|
|
2023
Q4 | $9K | Hold |
105
| – | – | ﹤0.01% | 538 |
|
|
2023
Q3 | $8K | Sell |
105
-100
| -49% | -$7.69K | ﹤0.01% | 541 |
|
|
2023
Q2 | $16K | Hold |
205
| – | – | 0.01% | 344 |
|
|
2023
Q1 | $17K | Hold |
205
| – | – | 0.01% | 344 |
|
|
2022
Q4 | $18K | Hold |
205
| – | – | 0.01% | 299 |
|
|
2022
Q3 | $13K | Hold |
205
| – | – | 0.01% | 383 |
|
|
2022
Q2 | $13K | Sell |
205
-69
| -25% | -$4.27K | 0.01% | 368 |
|
|
2022
Q1 | $16K | Sell |
274
-64
| -19% | -$4.09K | 0.01% | 357 |
|
|
2021
Q4 | $25K | Sell |
338
-89
| -21% | -$6.13K | 0.01% | 303 |
|
|
2021
Q3 | $30K | Sell |
427
-9
| -2% | -$632 | 0.01% | 279 |
|
|
2021
Q2 | $30K | Sell |
436
-49
| -10% | -$3.27K | 0.01% | 285 |
|
|
2021
Q1 | $31K | Buy |
485
+2
| +0.4% | +$129 | 0.01% | 272 |
|
|
2020
Q4 | $28K | Sell |
483
-94
| -16% | -$5.67K | 0.01% | 266 |
|
|
2020
Q3 | $36K | Buy |
577
+1
| +0.2% | +$69 | 0.01% | 225 |
|
|
2020
Q2 | $44K | Buy |
576
+443
| +333% | +$34K | 0.02% | 214 |
|
|
2020
Q1 | $10K | Buy |
133
+24
| +22% | +$1.66K | 0.01% | 300 |
|
|
2019
Q4 | $7K | Buy |
109
+1
| +0.9% | +$65 | ﹤0.01% | 372 |
|
|
2019
Q3 | $7K | Buy |
108
+1
| +0.9% | +$65 | ﹤0.01% | 364 |
|
|
2019
Q2 | $7K | Buy |
107
+1
| +0.9% | +$66 | ﹤0.01% | 375 |
|
|
2019
Q1 | $7K | Buy |
106
+1
| +1% | +$66 | ﹤0.01% | 365 |
|
|
2018
Q4 | $7K | Buy |
105
+1
| +1% | +$70 | ﹤0.01% | 346 |
|
|
2018
Q3 | $8K | Buy |
104
+1
| +1% | +$76 | ﹤0.01% | 369 |
|
|
2018
Q2 | $7K | Buy |
103
+2
| +2% | +$141 | ﹤0.01% | 399 |
|
|
2018
Q1 | $8K | Hold |
101
| – | – | ﹤0.01% | 368 |
|
|
2017
Q4 | $7K | Buy |
101
+1
| +1% | +$76 | ﹤0.01% | 381 |
|
|
2017
Q3 | $8K | Buy |
100
+85
| +567% | +$6.5K | ﹤0.01% | 360 |
|
|
2017
Q2 | $1K | Buy |
+15
| New | +$998 | ﹤0.01% | 511 |
|
|
2015
Q1 | – | Sell |
-39,623
| Closed | -$3.73M | – | 303 |
|
|
2014
Q4 | $3.73M | Sell |
39,623
-1,430
| -3% | -$148K | 2.31% | 11 |
|
|
2014
Q3 | $4.37M | Sell |
41,053
-5,770
| -12% | -$565K | 2.76% | 4 |
|
|
2014
Q2 | $3.88M | Buy |
+46,823
| New | +$3.64M | 2.31% | 12 |
|
|
2013
Q4 | – | Sell |
-50
| Closed | -$3K | – | 290 |
|
|
2013
Q3 | $3K | Hold |
50
| – | – | ﹤0.01% | 289 |
|
|
2013
Q2 | $3K | Buy |
+50
| New | +$2.61K | ﹤0.01% | 366 |
|
Other funds holding GILD
AlphaMark Advisors's GILD Position: Q4 2024 in Review
AlphaMark Advisors held its Gilead Sciences (GILD) position steady in Q4 2024 at 105 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #447.
AlphaMark Advisors first reported a position in GILD in Q2 2013 and has held it in 36 quarters since. The position peaked at $4.37M in Q3 2014. 1,888 funds tracked by Wall St. Rank hold GILD as of Q4 2024.
- AlphaMark Advisors held 105 shares of Gilead Sciences worth $10K as of Q4 2024.
- AlphaMark Advisors left its Gilead Sciences share count unchanged in Q4 2024.
- Gilead Sciences made up ﹤0.01% of AlphaMark Advisors's portfolio in Q4 2024, its #447 holding.
- AlphaMark Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 36 quarters since.
- AlphaMark Advisors's Gilead Sciences position peaked at $4.37M in Q3 2014.
- 1,888 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.
Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.